Chicago-area drug giant AbbVie is taking a $744 million punch to its first-quarter results, and its 2026 earnings outlook is getting trimmed in the process. The North Chicago-based pharma heavyweight told investors it will book a $744 million pre-tax charge tied to acquired in-process research and development and milestone payments, a hit that will shave about $0.41 from both GAAP and adjusted diluted earnings per share for the quarter. It is a textbook example of how aggressive, deal-fueled growth strategies can warp short-term numbers even as the company tries to build its future pipeline.
In AbbVie's Form 8-K, the company laid out the math: the $744 million pre-tax expense represents an unfavorable impact of $0.41 to both GAAP diluted EPS and adjusted non-GAAP diluted EPS. AbbVie also updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.96 to $14.16 to reflect the charge. The filing notes that results for the quarter ended March 31 are still being finalized and remain subject to the company’s normal financial-statement close process.
As reported by Crain's Chicago Business, the guidance tweak comes on the heels of a steady drumbeat of licensing deals and pipeline tie-ups that periodically drop chunky one-time expenses onto AbbVie’s income statement. People watching the stock are now trying to sort out whether this particular hit is tied to a single large milestone payment or a cluster of smaller deal obligations.
What drove the charge?
AbbVie booked the cost under “acquired IPR&D and milestones,” the bucket companies use when they license or buy clinical-stage drug candidates that still need development and regulatory work. Those charges tend to come in waves rather than smooth, predictable lines. AbbVie had already warned investors of roughly $2.7 billion in IPR&D and milestone expenses last October, according to Fierce Biotech, a reminder that dealmaking can make quarterly earnings look pretty bumpy.
AbbVie’s U.S. investment push stays on course
The company is stressing that this latest charge is non-operational and does not change its longer-term spending plans. In January, AbbVie pledged roughly $100 billion for U.S. research, development and capital projects in an agreement announced with the White House. Local projects are part of that story too, as AbbVie and state officials point to planned work at the North Chicago campus and related manufacturing efforts that, according to the company and the governor, are expected to boost capacity and jobs in the region.
For now, market watchers are parsing the 8-K and updated guidance while they wait for AbbVie’s full first-quarter results. Once the books are closed and the company provides more detail, investors and local stakeholders will be zeroing in on a line-by-line breakdown of which licenses, milestone payments or acquisitions created the $744 million figure and how each of those assets fits into AbbVie’s broader pipeline strategy.
